This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

For his top stock pick for 2009, market timing expert Sy Harding looks to medical products company, Zimmer Holdings (NYSE: ZMH).

In his Street Smart Report, the advisor looks at the maker of orthopedic implants, noting, "Currently trading at just 1.6 times books value, 2.3 times sales, and at 9.5 times earnings, the stock is a bargain."

Harding explains, "Zimmer designs and manufactures orthopedic implants, including joint, dental, and spinal replacements, as well as surgical instruments designed to aid in orthopedic surgery and post-operation rehabilitation.

"The company has been growing steadily from both rising sales of its own products, and from acquisitions. Its most recent acquisition was Abbott Spine, acquired from Abbott Labs for $360 million.

"The acquisition was funded from cash on hand and its already existing credit line, worth noting given how the credit crunch is causing problems for many companies. Zimmer's ratio of long-term debt to equity is only about 20% of its industry's average, and it maintains a high level of cash.

For 25 years, Steven Halpern, editor of TheStockAdvisors.com, has surveyed the leading financial newsletter advisors asking for their favorite stocks for the coming year. This article is one of 100+ ideas in the Best Stocks for 2008 report.

"Beijing-based biotech firm China Medical Technologies (NASDAQ: CMED) offers a unique product in a booming area -- non-invasive medical devices. CMED sells the High-Intensity Focused Ultrasound (HIFU) therapy system," says Mark Skousen, editor of Forecasts & Strategies and author of the just-released best seller, Investing in One Lesson.

"This system uses an ultrasound-guided ablation technique that is used for the non-invasive treatment of liver, breast, and kidney tumors; solid tumors in the pelvic cavity or bone; and tumors in the four limbs or superficial tissues. The HIFU system has been wildly successful in China, and now is expanding elsewhere.

"Countries such as Japan and Korea have approved its high-intensity focused ultrasound (HIFU) tumor therapy systems for the treatment of liver, pancreatic, and uterine cancer.

"China Medical is really taking off with rising earnings growth projected to occur in 2008, 2009 and 2010, amid further acceptance of the HIFU technology worldwide. Acceptance of that technology will drive international revenues, starting in Korea, Europe, Japan, and the United States.